Global Erythropoiesis Stimulating Agents Market Overview

The Global Erythropoiesis Stimulating Agents Market Is estimated to reach USD 14.8 billion by 2030, growing at a CAGR of 4.3% from 2022 to 2030. It was valued at USD 8.2 billion in 2022.

Erythropoietin in the human body is a hormone like substance secreted by the kidneys and liver, which can promote red blood cell production. Erythropoietin can increase blood flow specific solubility (increase the percentage of red blood cells in the blood) in patients with kidney disease anemia. EPO stimulants are artificially synthesized based on the principle of erythropoietin, which can promote the generation of oxygen in muscles, thereby making muscles stronger and working longer. Agents promoting the synthesis of red blood cells are known as erythropoiesis stimulating agents.

Erythropoiesis stimulating agents recommended for the treatment of anemia. Erythropoietin (EPO) is an essential hematopoietic growth factor for red blood cell proliferation, differentiation, and maintenance of standard numbers of peripheral circulating red blood cells in the body.

Global Erythropoiesis Stimulating Agents Market Insights

The rise in the incidence of anemia cases worldwide is likely to robust the growth of the global Erythropoiesis Stimulating Agents market in the estimated period. Additionally, the rising awareness about erythropoiesis stimulating agent therapies across the globe leads to the growth of the global Erythropoiesis Stimulating Agents market. Moreover, the surge in demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin is estimated to drive the global Erythropoiesis Stimulating Agents market in the upcoming periods.

As per the World Health Organization, anemia is among the several complications of chronic kidney disease, with a prevalence of about 15% in the United States. More than 50% of patients with advanced disease develop anemia. Further, the growing incidence of chronic kidney disease worldwide is propelling an exponential growth in the global Erythropoiesis Stimulating Agents market in the future timeline. According to WHO 2015 study estimated that 1.2 million people died from kidney failure, an increase of 32% since 2005. Additionally, each year, around 1.7 million people die from acute kidney injury. Overall, about 5–10 million people die annually from kidney disease.

Besides, an increase in the number of new cancer cases and the rapid surge in tumor disease expected to accelerate the global Erythropoiesis Stimulating Agents market. The World Health Organization expects the number of cases related to cancer will increase by 70%, from 14 million in 2012 to 18.1 million in 2018 and 24 million by 2035.

Growth Driver

The increasing number of patients suffering from anemic condition induced due to cancer, HIV, and kidney failures

The global incidence of chronic kidney disease has increased dramatically, and chronic kidney disease has become a public health problem across the globe. Changes in age and epidemiological trends have significantly increased the incidence of chronic kidney disease worldwide. According to WHO, the global prevalence of chronic kidney disease (CKD) increased by 88.76%, the prevalence increased by 86.95%, and deaths.

A rising number of cancer patients and the surge in the incidence of tumor-related anemia

The increasing number of new cancer cases and prolonging survival time will increase the number of patients. Globally, malignant tumors are a threat to human health. The incidence of tumor-associated anemia is as high as 60% Cancer-related anemia (CRA). Anemia that occurs during development and treatment is one of the common concomitant diseases of malignant tumors.

Rising awareness about erythropoiesis stimulating agent therapies

Erythropoiesis Stimulating Agents increase the number of red blood cells, used for anemia, tissue separation, premature babies, used in cancer and hematology. The demand for erythropoiesis stimulating agents is rapidly increasing due to the rising prevalence of chronic kidney disease, cancer, and the growing demand for cheaper erythropoietin drugs.

Product Type Segmental Analysis

Based on Product Type, the global Erythropoiesis Stimulating Agents Market categorized into Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Epoetin-Theta, and Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta). The Epoetin Alfa segment projected to lead the market, owing to the augmentation in demand of Epoetin Alfa for treatment of anemia (low red blood cell count) in people with chronic kidney failure, and people are receiving chemotherapy. Darbepoetin Alfa will drive by more number of approved products for prescription in this segment in comparison to others for anemia caused by renal disorders.

Application Segmental Analysis

Based on the Application, the Global Erythropoiesis Stimulating Agents Market classified into Cancer, Renal Disorders, Anti-retroviral Treatment, Neural diseases, and others. The Cancer segment anticipated to dominate the market as the patients with cancer-related anemia is commonly prescribed by erythropoietin in the form of epoetin alfa and epoetin beta. Renal Disorders segment will grow by renal anemia, which predominantly rises due to relative erythropoietin (EPO) deficiency.

Distribution Channel Segmental Analysis

Based on the distribution channel, the Global Erythropoiesis Stimulating Agents Market segmented into Offline Channel and Online Channel. The Offline Channel segment will dominate the market due to population, which is still dependent on conventional distribution channels such as pharmacies at the hospital, ambulatory surgical centers, and retail pharmacies. Online Channels will drive by the rising number of internet users and the availability of online platforms to purchase pharmaceutical products.

Region Segmental Analysis

Based on geography, the global Erythropoiesis Stimulating Agents market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America expected to dominate the market attributed to the availability of effective treatments for various chronic diseases, like cancer, chronic kidney disease (CKD), neural, and HIV infections, along with increasing investments in the R&D activities from both government and private entities. According to the CDC, in 2016, about 29 million people had diabetes, while about 86 million were in the pre-diabetic stage.

The European market will drive by the emerging economies and new products with better efficacy, which will be a significant opportunity for the erythropoietin stimulating agents market.

Competitor Analysis

Companies such as Biocon, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Amgen Inc., Hoffmann-La Roche, Biosidus, Thermo Fisher Scientific, F. Hoffmann La Roche, Pfizer, and Ranbaxy Laboratories Ltd are the key players in the Global Erythropoiesis Stimulating Agents Market.

Key Stakeholders

• Market research and consulting firms
• Industry associations
• Global Erythropoiesis Stimulating Agents Service Providers
• Research organizations and consulting companies
• Organizations, associations, and alliances related to Erythropoiesis-Stimulating Agents
• Regulatory bodies

Scope of the report

Recent Developments

1. In September 2021, Luspatercept received marketing authorization through the European Union (EU) for the treatment of patients with myelodysplastic syndrome (MDS) or transfusion-dependent beta-thalassemia (BT).
2. In August 2021, Dosis expanded its kidney care platform with Iron Advisor Tool to personalize anemia management.
3. In August 2021, The European Commission (EC) approved Astellas’ Evrenzo™ for the treatment of chronic kidney disease-related anemia.

The objective of the Research

• Market Modelling Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
• Product Analysis Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
• Market Trend and Economic Factors Analysis This analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
• Market Segmental Analysis Segmental analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
• Geographical Mapping The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.

Market Modelling

By Product Type

• Epoetin Alfa
• Epoetin Beta
• Darbepoetin Alfa
• Epoetin-Theta
• Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

By Application

• Cancer
• Renal Disorders
• Anti-retroviral Treatment
• Neural diseases
• Others

By Distribution Channel

• Offline Channel
• Online Channel

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Patient Data Management Market

Diabetic Footwear Market

Electric Vehicle Fluid Market

India Video KYC Market Excel Data

Electric Commercial Vehicle Market

Hollow Structural Sections Market

Fluorinated Plasma Surface Treatment Market

Automotive Piston Market

Building Window Cleaning System Market

Automotive Industry Trends

Report Content

1.     Research Strategic Development

1.1. Market Modelling

1.2. Product Analysis

1.3. Market Trend and Economic Factors Analysis

1.4. Market Segmental Analysis

1.5. Geographical Mapping

1.6. Country Wise Segregation

2.     Research Methodology

2.1. Identification of Target Market

2.2. Data Acquisition

2.3. Refining of Data/ Data Transformations

2.4. Data Validation through Primary Techniques

2.5. Exploratory Data Analysis

2.6. Graphical Techniques/Analysis

2.7. Quantitative Techniques/Analysis

2.8. Visual Result/Presentation

3.     Executive Summary
4.     Market Insights

4.1. Supply Chain Analysis

4.2. Economic Factor Analysis

4.2.1. Drivers

4.2.2. Trends

4.2.3. Opportunities

4.2.4. Challenges

4.3. Technological Landscape

4.4. Competitors & Product Analysis

4.5. Regulatory Framework

4.6. Company market share analysis, 2022

4.7. Porter’s Five forces analysis

4.8. Price point analysis

4.9. New Investment Analysis

4.10.            PESTEL Analysis

5.     Global Erythropoiesis Stimulating Agents Market Overview

5.1. Market Size & Forecast,2017-2030

5.1.1. Demand

5.1.1.1. By Value (USD Billion)

5.2. Market Share & Forecast, 2017-2030

5.2.1.     By Product Type

5.2.1.1.            Epoetin Alfa

5.2.1.2.            Epoetin Beta

5.2.1.3.            Darbepoetin Alfa

5.2.1.4.            Epoetin-Theta

5.2.1.5.            Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

5.2.2.     By Application

5.2.2.1.            Cancer

5.2.2.2.            Renal Disorders

5.2.2.3.            Anti-retroviral Treatment

5.2.2.4.            Neural diseases

5.2.2.5.            Others

5.2.3.     By Distribution Channel

5.2.3.1.            Offline Channel

5.2.3.2.            Online Channel

5.2.4.     By Region

5.2.4.1.            North America

5.2.4.2.            Europe

5.2.4.3.            Asia-Pacific

5.2.4.4.            South America

5.2.4.5.            The Middle East & Africa

6.     North America Erythropoiesis Stimulating Agents Market Overview

6.1. North America Erythropoiesis Stimulating Agents Market Size & Forecast,2017-2030

6.1.1. Demand

6.1.1.1. By Value (USD Billion)

6.2. Market Share & Forecast, 2017-2030

6.2.1. By Product Type

6.2.1.1.            Epoetin Alfa

6.2.1.2.            Epoetin Beta

6.2.1.3.            Darbepoetin Alfa

6.2.1.4.            Epoetin-Theta

6.2.1.5.            Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

6.2.2. By Application

6.2.2.1.            Cancer

6.2.2.2.            Renal Disorders

6.2.2.3.            Anti-retroviral Treatment

6.2.2.4.            Neural diseases

6.2.2.5.            Others

6.2.3. By Distribution Channel

6.2.3.1.            Offline Channel

6.2.3.2.            Online Channel

6.2.4. By Country

6.2.4.1.            US

6.2.4.2.            Canada

6.2.4.3.            Mexico

6.2.5. Company Market Share (Top 3-5)

6.2.6. Economic Impact Study on North America Erythropoiesis Stimulating Agents Market

7.     Europe Erythropoiesis Stimulating Agents Market Overview

7.1. Europe Erythropoiesis Stimulating Agents Market Size & Forecast,2017-2030

7.1.1. Demand

7.1.1.1. By Value (USD Billion)

7.2. Market Share & Forecast, 2017-2030

7.2.1. By Product Type

7.2.1.1.            Epoetin Alfa

7.2.1.2.            Epoetin Beta

7.2.1.3.            Darbepoetin Alfa

7.2.1.4.            Epoetin-Theta

7.2.1.5.            Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

7.2.2. By Application

7.2.2.1.            Cancer

7.2.2.2.            Renal Disorders

7.2.2.3.            Anti-retroviral Treatment

7.2.2.4.            Neural diseases

7.2.2.5.            Others

7.2.3. By Distribution Channel

7.2.3.1.            Offline Channel

7.2.3.2.            Online Channel

7.2.4. By Country

7.2.4.1.            Germany

7.2.4.2.            UK

7.2.4.3.            France

7.2.4.4.            Italy

7.2.4.5.            Rest of Europe

7.2.5.      Company Market Share (Top 3-5)

7.2.6.      Economic Impact Study on Europe Erythropoiesis Stimulating Agents Market

8.     Asia-Pacific Erythropoiesis Stimulating Agents Market Overview

8.1. Asia-Pacific Erythropoiesis Stimulating Agents Market Size & Forecast,2017-2030

8.1.1. Demand

8.1.1.1. By Value (USD Billion)

8.2. Market Share & Forecast, 2017-2030

8.2.1. By Product Type

8.2.1.1.            Epoetin Alfa

8.2.1.2.            Epoetin Beta

8.2.1.3.            Darbepoetin Alfa

8.2.1.4.            Epoetin-Theta

8.2.1.5.            Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

8.2.2. By Application

8.2.2.1.            Cancer

8.2.2.2.            Renal Disorders

8.2.2.3.            Anti-retroviral Treatment

8.2.2.4.            Neural diseases

8.2.2.5.            Others

8.2.3. By Distribution Channel

8.2.3.1.            Offline Channel

8.2.3.2.            Online Channel

8.2.4. By Country

8.2.4.1.            India

8.2.4.2.            Japan

8.2.4.3.            Australia

8.2.4.4.            Rest of Asia Pacific

8.2.5.      Company Market Share (Top 3-5)

8.2.6.      Economic Impact Study on Asia Pacific Erythropoiesis Stimulating Agents Market

9.     South America Erythropoiesis Stimulating Agents Market Overview

9.1. South America Erythropoiesis Stimulating Agents Market Size & Forecast,2017-2030

9.1.1. Demand

9.1.1.1. By Value (USD Billion)

9.2. Market Share & Forecast, 2017-2030

9.2.1. By Product Type

9.2.1.1.            Epoetin Alfa

9.2.1.2.            Epoetin Beta

9.2.1.3.            Darbepoetin Alfa

9.2.1.4.            Epoetin-Theta

9.2.1.5.            Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

9.2.2. By Application

9.2.2.1.            Cancer

9.2.2.2.            Renal Disorders

9.2.2.3.            Anti-retroviral Treatment

9.2.2.4.            Neural diseases

9.2.2.5.            Others

9.2.3. By Distribution Channel

9.2.3.1.            Offline Channel

9.2.3.2.            Online Channel

9.2.4. By Country

9.2.4.1.            Brazil

9.2.4.2.            Argentina

9.2.4.3.            Rest of South America

9.2.5.      Company Market Share (Top 3-5)

9.2.6.      Economic Impact Study on South America Erythropoiesis Stimulating Agents Market

10. The Middle East & Africa Erythropoiesis Stimulating Agents Market Overview

10.1.            The Middle East & Africa Erythropoiesis Stimulating Agents Market Size & Forecast,2017-2030

10.1.1.                        Demand

10.1.1.1.        By Value (USD Billion)

10.2.            Market Share & Forecast, 2017-2030

10.2.1.                        By Product Type

10.2.1.1.        Epoetin Alfa

10.2.1.2.        Epoetin Beta

10.2.1.3.        Darbepoetin Alfa

10.2.1.4.        Epoetin-Theta

10.2.1.5.        Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

10.2.2.                        By Application

10.2.2.1.        Cancer

10.2.2.2.        Renal Disorders

10.2.2.3.        Anti-retroviral Treatment

10.2.2.4.        Neural diseases

10.2.2.5.        Others

10.2.3.                        By Distribution Channel

10.2.3.1.        Offline Channel

10.2.3.2.        Online Channel

10.2.4.                        By Country

10.2.4.1.  Saudi Arabia

10.2.4.2.  UAE

10.2.4.3.  South Africa

10.2.4.4.  Rest of the Middle East & Africa

10.2.5.                    Company Market Share (Top 3-5)

10.2.6.                    Economic Impact Study on Middle East & Africa Erythropoiesis Stimulating Agents Market

11. Competitor Analysis

11.1.   Company Description

11.2.   Financial Analysis

11.3.   Key Products

11.4.   Key Management Personnel

11.5.   Contact Address

11.6.   SWOT Analysis

11.7.   Company Profile

11.7.1. Biocon

11.7.2. Johnson & Johnson

11.7.3. Teva Pharmaceutical Industries Ltd.

11.7.4. Intas Pharmaceutical

11.7.5. Amgen Inc.

11.7.6. Hoffmann-La Roche

11.7.7. Biosidus

11.7.8. Thermo Fisher Scientific

11.7.9. Hoffmann La Roche

11.7.10.                        Pfizer

11.7.11.                        Ranbaxy Laboratories Ltd

11.7.12.                        Other Prominent Players